Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study

References

• Siegel RL , Miller KD , Jemal A , et al. Cancer Statistics, 2020. CA Cancer J Clin . 2020;70(1):7–30. doi:10.3322/caac.21590 31912902
   PubMed Web of Science ®Google Scholar
• Chen W , Zheng R , Baade PD , et al. Cancer statistics in China, 2015. CA Cancer J Clin . 2016;66(2):115–132. doi:10.3322/caac.21338 26808342
   PubMed Web of Science ®Google Scholar
• Nagasaka M , Gadgeel SM . Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther . 2018;18(1):63–70. doi:10.1080/14737140.2018.1409624 29168933
   PubMed Web of Science ®Google Scholar
• Priti SH , Jeffrey JW , Christoph M , et al. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol . 2017;52(2):117–124. doi:10.1016/j.semcancer.2017.12.002 29229461
   PubMed Web of Science ®Google Scholar
• Lin B , Song X , Yang D , et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR-βand FGFR1. Gene . 2018;654(undefined):77–86. doi:10.1016/j.gene.2018.02.026 29454091
   PubMed Web of Science ®Google Scholar
• Syed YY . Anlotinib: first Global Approval. Drugs . 2018;78(10):1057–1062. doi:10.1007/s40265-018-0939-x 29943374
   PubMed Web of Science ®Google Scholar
• Han B , Li K , Wang Q , et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA ONCOL . 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039 30098152
   PubMed Web of Science ®Google Scholar
• Zhou C , W YL , Chen G , et al. BEYOND: A Randomized, double-blind, placebo-controlled, multicenter, phase iii study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol . 2015;33(19):2197–2204. doi:10.1200/JCO.2014.59.4424 26014294
   PubMed Web of Science ®Google Scholar
• Garon EB , Ciuleanu TE , Arrieta O , et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet . 2014;384(9944):665–673. doi:10.1016/S0140-6736(14)60845-X 24933332
   PubMed Web of Science ®Google Scholar
• Georganaki M , Hooren L , Dimberg A . Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol . 2018;9(undefined):3081. doi:10.3389/fimmu.2018.03081 30627131
   PubMed Web of Science ®Google Scholar
• Miller KD , Nogueira L , Mariotto AB , et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin . 2019;69(5):363–385. doi:10.3322/caac.21565 31184787
   PubMed Web of Science ®Google Scholar
• Wang D , Wang W , Zhu B , Wang X . Lung cancer heterogeneity and new strategies for drug therapy. Annu Rev Pharmacol Toxicol . 2018;58(1):531–546. doi:10.1146/annurev-pharmtox-010716-104523 28977762
   PubMed Web of Science ®Google Scholar
• Lin JJ , Shaw AT . Resisting resistance: targeted therapies in lung cancer. Trends Cancer . 2016;2(7):350–364. doi:10.1016/j.trecan.2016.05.010 27819059
   PubMed Web of Science ®Google Scholar
• Morgillo F , Della Corte CM , Fasano M , et al. Mechanisms of resistance to EGFR- targeted drugs: lung cancer. ESMO Open . 2016;1(3). doi:10.1136/esmoopen-2016-000060.
   Google Scholar
• Han B , Li K , Zhao Y , et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302. Br J Cancer . 2018;118(5):654–661. doi:10.1038/bjc.2017.478 29438373
   PubMed Web of Science ®Google Scholar
• Yang SJ , Zhang W , Chen Q , et al. Clinical investigation of the efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy: aretrospective study. Cancer Manag Res . 2020;12:10333–10340. doi:10.2147/CMAR.S280096 33116888
   PubMed Web of Science ®Google Scholar
• Saito H , Fukuhara T , Furuya N , et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol . 2019;20(5):625–635. doi:10.1016/S1470-2045(19)30035-X 30975627
   PubMed Web of Science ®Google Scholar
• Zhao L , Cai X , Chen D , et al. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant. Radiation Oncol . 2020;15:1. doi:10.1186/s13014-019-1454-2
   Web of Science ®Google Scholar
• Yu X , Fan Y . Real-world data on prognostic factors for overall survival in egfr-mutant non-small-cell lung cancer patients with brain metastases. J Cancer . 2019;10(15):3486–3493. doi:10.7150/jca.30292 31293653
   PubMed Web of Science ®Google Scholar
• Castañón E , Rolfo C , Viñal D , et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastases. J Transl Med . 2015;257(13).
   Google Scholar
• Sørensen JB , Hansen HH , Hansen M , et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol . 1988;6(9):1474–1480. doi:10.1200/JCO.1988.6.9.1474 3047337
   PubMed Web of Science ®Google Scholar
• Reck M , Mok T , Nishio M , et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med . 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-0 30922878
   PubMed Web of Science ®Google Scholar
• Ciciola P , Cascetta P , Bianco C , et al. Combining immune checkpoint inhibitors with anti-angiogenic agents. J Clin Med . 2020;9(3):675. doi:10.3390/jcm9030675
   PubMed Web of Science ®Google Scholar
• Herbst RS , Arkenau HT , Santana-Davila R , et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol . 2019;20(8):1109–1123. doi:10.1016/S1470-2045(19)30458-9 31301962
   PubMed Web of Science ®Google Scholar
• Shao L , Wang W , Song Z , et al. The efficacy and safety of anlotinib treatment for advanced lung cancer. Onco Targets Ther . 2019;12:6549–6554. doi:10.2147/OTT.S205674 31616163
   PubMed Web of Science ®Google Scholar
• Yao J , Wang Z , Sheng J , et al. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: atwo-center retrospective study. Int Immunopharmacol . 2020;89. doi:10.1016/j.intimp.2020.107033
   PubMed Web of Science ®Google Scholar
• Zhu X . Anlotinib combined with whole brain radiation therapy (WBRT) for advanced non-small lung cancer with multiple brain metastases: An open-label, single-arm phase II trial. ESMO. 2020;1386p. doi:10.1016/j.ijrobp.2020.03.038
   Google Scholar